2018
DOI: 10.1007/s40263-018-0517-5
|View full text |Cite
|
Sign up to set email alerts
|

The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review

Abstract: The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of safety data for the use of SGAs during pregnancy is rapidly increasing, thus constantly changing the level of evidence. We performed a clinically focused review on the safety of SGA during pregnancy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
49
0
5

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 73 publications
(55 citation statements)
references
References 55 publications
1
49
0
5
Order By: Relevance
“…For antipsychotic drugs (APs), the amount of data is less impressive, and the amount of safety data available has been lagging the transition from usage patterns from first‐generation antipsychotics (FGAPs) to second‐generation antipsychotics (SGAPs) . During the last 5 years, a substantial amount of safety data has emerged for the SGAP olanzapine and quetiapine especially , while data for other SGAP remain relatively scarce . Antiepileptic drugs (AEDs), used as mood stabilizers within psychiatry, are poorly evaluated for safety during pregnancy except for lamotrigine, which is considered safe, and valproate, which poses a significant risk of major congenital malformations .…”
Section: Introductionmentioning
confidence: 99%
“…For antipsychotic drugs (APs), the amount of data is less impressive, and the amount of safety data available has been lagging the transition from usage patterns from first‐generation antipsychotics (FGAPs) to second‐generation antipsychotics (SGAPs) . During the last 5 years, a substantial amount of safety data has emerged for the SGAP olanzapine and quetiapine especially , while data for other SGAP remain relatively scarce . Antiepileptic drugs (AEDs), used as mood stabilizers within psychiatry, are poorly evaluated for safety during pregnancy except for lamotrigine, which is considered safe, and valproate, which poses a significant risk of major congenital malformations .…”
Section: Introductionmentioning
confidence: 99%
“…Zunächst gab es Bedenken wegen Tierversuchen, die Hinweise für teratogene Effekte bei Exposition mit Aripipazol in der Schwangerschaft zeigten. Mittlerweile gibt es jedoch ausreichend humane Daten, die keine Hinweise für ein erhöhtes Malformationsrisiko zeigen [11,19].…”
Section: Aripiprazolunclassified
“…Generation werden in der Reihung Olanzapin, Quetiapin > Risperidon, Clozapin empfohlen. Eine Indikation zum Schwangerschaftsabbruch bei akzidenteller Exposition in der Frühschwangerschaft besteht bei keinem Antipsychotikum [4] [10] [8].…”
Section: Antipsychotikaunclassified